A5053474378- Hematopoietic Stem Cell Transplantation
- Multiple Myeloma Research and Treatments
- CAR-T cell therapy research
- Protein Degradation and Inhibitors
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Lymphoma Diagnosis and Treatment
- Renal Transplantation Outcomes and Treatments
- Hedgehog Signaling Pathway Studies
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Immune Cell Function and Interaction
- Oral and gingival health research
- Polyomavirus and related diseases
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Vitamin D Research Studies
- Biosimilars and Bioanalytical Methods
- Peptidase Inhibition and Analysis
- COVID-19 Clinical Research Studies
- T-cell and B-cell Immunology
- Virus-based gene therapy research
- Mesenchymal stem cell research
- SARS-CoV-2 and COVID-19 Research
- Integrated Circuits and Semiconductor Failure Analysis
- Immunodeficiency and Autoimmune Disorders
Centro de Investigación del Cáncer
2015-2025
Instituto de Investigación Biomédica de Salamanca
2016-2025
Centro de Investigación Biomédica en Red de Cáncer
2019-2025
Complejo Hospitalario de Salamanca
2015-2025
Centre for Biomedical Network Research on Rare Diseases
2024-2025
Universidad de Salamanca
2013-2025
Instituto de Salud Carlos III
2024
Centro de Investigación Biomédica en Red
2021-2024
Hospital Clínico San Carlos
2024
Center of Regenerative Medicine in Barcelona
2024
For patients with smoldering multiple myeloma, the standard of care is observation until symptoms develop. However, this approach does not identify high-risk who may benefit from early intervention.In randomized, open-label, phase 3 trial, we randomly assigned 119 myeloma to treatment or observation. Patients in group received an induction regimen (lenalidomide at a dose 25 mg per day on days 1 21, plus dexamethasone 20 4 and 12 15, 4-week intervals for nine cycles), followed by maintenance...
This study reports on 382 COVID-19 patients having undergone allogeneic (n = 236) or autologous 146) hematopoietic cell transplantation (HCT) reported to the European Society for Blood and Marrow Transplantation (EBMT) Spanish Group of Hematopoietic Stem Cell (GETH). The median age was 54.1 years (1.0-80.3) allogeneic, 60.6 (7.7-81.6) HCT patients. time from 15.8 months (0.2-292.7) in 24.6 (-0.9 350.3) recipients. 83.5% developed lower respiratory tract disease 22.5% were admitted an ICU....
Abstract Tisagenlecleucel (tisa‐cel) is a second‐generation autologous CD19‐targeted chimeric antigen receptor (CAR) T‐cell therapy approved for relapsed/refractory (R/R) large B‐cell lymphoma (LBCL). The approval was based on the results of phase II JULIET trial, with best overall response rate (ORR) and complete (CR) in infused patients 52% 40%, respectively. We report outcomes tisa‐cel standard‐of‐care (SOC) setting R/R LBCL. Data from all LBCL who underwent leukapheresis December 2018...
Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-targeted chimeric antigen receptor (CAR) T cells approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We performed a retrospective study to evaluate safety efficacy of axi-cel tisa-cel outside the setting clinical trial. Data from consecutive patients with R/R LBCL who underwent apheresis or were retrospectively collected 12 Spanish centers. A total 307 (n=152) (n=155) November 2018 August 2021, which...
Approximately 30%-40% of patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) infused CD19-targeted chimeric antigen receptor (CAR) T cells achieve durable responses. Consensus guidelines suggest avoiding bendamustine before apheresis, but specific data in this setting are lacking. We report distinct outcomes after CAR T-cell therapy according to previous exposure.
Background Although Hodgkin’s lymphoma is a highly curable disease with modern chemotherapy protocols, some patients are primary refractory or relapse after first-line even high-dose therapy and autologous stem cell transplantation. We investigated the potential role of allogeneic transplantation in this setting.Design Methods In phase II study 92 relapsed an HLA-identical sibling, matched unrelated donor one antigen mismatched, were treated salvage followed by reduced intensity Fourteen...
Genetic aberrations detected in multiple myeloma (MM) have also been reported the premalignant conditions monoclonal gammopathy of undetermined significance (MGUS) and smoldering MM (SMM). Our aim was to investigate depth level clonal heterogeneity recurrent genetic abnormalities these conditions.Immunoglobulin heavy chain (IGH) translocations, 13q14 17p13 deletions, 1q21 gains using FISH were evaluated 90 MGUS, 102 high-risk SMM, 373 MM. To this end, we not only purified plasma cells (PC)...
We evaluated the feasibility, safety, and efficacy of administration 4 sequential doses (intravenously administered on days 1, 4, 11, 18) cryopreserved bone marrow-derived mesenchymal stromal cells (MSC) expanded with platelet lysate obtained from third-party donors as a second-line treatment for steroid-refractory acute graft-versus-host (aGVHD) disease in series 25 patients. All patients received at least 2 MSC, whereas 21 3 18 initially planned doses. Because achievement partial response,...
PURPOSE.To develop a tear molecule level-based predictive model based on panel of cytokines and their correlation with clinical features in ocular chronic graft versus host disease (cGVHD). METHODS.Twenty-two cGVHD patients 21 healthy subjects were evaluated controlled environmental research laboratory (CERLab).Clinical parameters recorded, tears collected.Levels 15 molecules (epidermal growth factor [EGF], IL receptor antagonist [IL-1Ra], IL-1b, IL-2, IL-6, IL-8/CXCL8, IL-10, IL-12p70,...
Graft-versus-host disease is the main cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. First-line treatment based on use high doses corticosteroids. Unfortunately, second-line for both acute chronic graft-versus-host disease, remains a challenge. Ruxolitinib has been shown as an effective safe option these patients. Seventy-nine patients received ruxolitinib were evaluated in this retrospective multicenter study. Twenty-three refractory median 3...
This is a multicenter prospective observational study that included large cohort (n = 397) of allogeneic (allo-HSCT; 311) and autologous (ASCT) hematopoietic stem cell transplant 86) recipients who were monitored for antibody detection within 3-6 weeks after complete severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination from February 1, 2021, to July 20, 2021. Most patients 387, 97.4%) received mRNA-based vaccines. the (93%) vaccinated more than 1 year transplant....
(1) Background: New therapeutic strategies have improved the prognosis of multiple myeloma (MM), changing accepted view this disease from being incurable to treatable. (2) Methods: We studied 1001 patients with MM between 1980 and 2020, grouping into ten-year periods by diagnosis 1980–1990, 1991–2000, 2001–2010 2011–2020. (3) Results: After 65.1 months follow-up, median OS cohort was 60.3 months, increased significantly over time: 22.4 in 37.4 61.8 103.6 2011–2020 (p < 0.001). Using novel...
Abstract The long-term clinical efficacy of SARS-CoV-2 vaccines according to antibody response in immunosuppressed patients such as hematological has been little explored. A prospective multicenter registry-based cohort study conducted from December 2020 July 2022 by the Spanish Transplant and Cell Therapy group, was used analyze relationship over time after full vaccination (at 3–6 weeks, 3, 6 12 months) (2 doses) booster doses with breakthrough infection 1551 disorders. At a median...
Over 60% of relapsed/refractory (R/R) large B-cell lymphoma (LBCL) patients who receive chimeric antigen receptor (CAR) T cells will experience disease progression. There is no standard next line therapy and information in this setting scarce heterogeneous. We analyzed 387 R/R LBCL progressed after CAR from July 2018 until March 2022 Spain the United Kingdom. Median overall survival (OS) was 5.3 months, with significant differences according to interval between infusion progression (<2...
BK virus-associated hemorrhagic cystitis (BKV-HC) is a severe complication after allogeneic hematopoietic stem cell transplantation (HSCT), but antiviral treatment for this condition has not been evaluated.We conducted retrospective survey on the safety and outcome of cidofovir patients with BKV-HC in centers affiliated European Group Blood Marrow Transplantation.From 1 April 2004 to 31 December 2007, 62 received diagnosis median interval 35 days HSCT (range, 3-577 days). Fifty-seven (92%)...